ASND vs SNY
Ascendis Pharma A/S and Sanofi, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | SNY |
|---|---|---|
| Revenue | €720.1M | €43.6B |
| Net income | €-228.0M | €7.8B |
| Gross margin | 86.8% | 77.2% |
| Net margin | −31.7% | 18.0% |
| Return on equity | · | 10.5% |
| Diluted EPS | −€3.76 | €6.37 |
| Dividend / share | · | €3.92 |
| Payout ratio | · | 61.1% |
| Free cash flow | · | · |
| Equity | · | €71.4B |
| Net debt / equity | · | 0.15× |
| Current ratio | 1.04× | 1.09× |
| Revenue CAGR 5y | 153.0% | 3.9% |
| Profit CAGR 5y | · | −8.7% |
SNY bills 60.6× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ASND | SNY |
|---|---|---|
| FY2025 | €720.1M | €43.6B |
| FY2024 | €363.6M | €41.1B |
| FY2023 | €266.7M | €37.8B |
| FY2022 | €51.2M | €37.7B |
| FY2021 | €7.8M | €37.8B |
| FY2020 | €7.0M | €36.0B |
| FY2019 | €13.4M | €36.1B |
| FY2018 | €10.6M | €34.5B |
| FY2017 | €1.5M | €35.1B |
| FY2016 | €4.6M | €33.8B |
Bottom line
| Fiscal year | ASND | SNY |
|---|---|---|
| FY2025 | €-228.0M | €7.8B |
| FY2024 | €-378.1M | €5.6B |
| FY2023 | €-481.4M | €5.4B |
| FY2022 | €-583.2M | €8.4B |
| FY2021 | €-383.6M | €6.2B |
| FY2020 | €-419.0M | €12.3B |
| FY2019 | €-218.0M | €2.8B |
| FY2018 | €-130.1M | €4.3B |
| FY2017 | €-123.9M | €8.4B |
| FY2016 | €-68.5M | €4.7B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€42,905,868,000 | SNY |
| FY2024 | −€40,717,359,000 | SNY |
| FY2023 | −€37,550,282,000 | SNY |
| FY2022 | −€37,599,826,000 | SNY |
| FY2021 | −€37,753,222,000 | SNY |
| FY2020 | −€36,034,047,000 | SNY |
| FY2019 | −€36,112,625,000 | SNY |
| FY2018 | −€34,452,419,000 | SNY |
| FY2017 | −€35,070,470,000 | SNY |
| FY2016 | −€33,804,394,000 | SNY |
| FY2015 | −€34,051,882,000 | SNY |
SNY has reported the higher revenue in every one of these 11 fiscal years. The gap has widened since the earliest year compared.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −49.7 pp | SNY |
| FY2024 | −117.6 pp | SNY |
| FY2023 | −194.9 pp | SNY |
| FY2022 | −1162.2 pp | SNY |
| FY2018 | −1242.3 pp | SNY |
| FY2015 | −418.4 pp | SNY |
SNY has kept the higher net margin in every one of these 6 fiscal years.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than SNY's over the 6 comparable fiscal years — 487.7 percentage points of standard deviation against 3.5.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
SNY led in net margin in every one of the 6 comparable fiscal years — a structural lead, not a recent swing.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than SNY's over the 8 comparable fiscal years — 20.4 percentage points of standard deviation against 4.6.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
SNY led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.